Tumour imaging has significantly evolved in recent years thanks to technological advancements and a better understanding of tumour biology. These developments have enabled the early detection and monitoring of tumours, significantly improving patient outcomes. This article will discuss various tumour imaging techniques, highlighting their advantages, disadvantages, and applications.
Computed Tomography (CT) scans utilise X-ray images to produce detailed, cross-sectional images of the body’s internal structures, including tumours. CT scans are widely used to identify tumours, determine their size and location, and assess whether they have spread to other tissues. The advantages of CT scans include their speed and accuracy in detecting tumours. However, CT scans expose patients to ionising radiation, which can be harmful in high doses.
Magnetic Resonance Imaging (MRI) uses powerful magnets and radio waves to generate detailed images of the body’s internal structures. Unlike CT scans, MRI does not use ionising radiation, making it safer for patients. MRI can distinguish between healthy and cancerous tissues, providing valuable information on tumour size, location, and possible infiltration into surrounding structures. MRI’s main drawback is its cost, making it less accessible for some patients.
Positron Emission Tomography (PET) is a functional imaging technique that detects metabolic changes associated with tumours. PET scans use a small amount of radioactive material introduced into the body through intravenous injection. Cancer cells typically have a higher metabolic rate than healthy cells, allowing them to absorb the radioactive substance more quickly. This increased uptake can be visualised on PET scans, highlighting areas of potential cancer. PET scans are useful for detecting metastatic tumours and monitoring tumour response to therapy. The main disadvantages of PET scans include their cost and exposure to ionising radiation.
Ultrasound imaging uses high-frequency sound waves to produce real-time images of the body’s internal structures. It is a non-invasive, radiation-free method for visualising tumours and assessing their size, location, and blood supply. Ultrasound is widely accessible, cost-effective, and safe for patients. However, its image quality is lower than CT, MRI, and PET scans, sometimes limiting its usefulness.
Optical imaging techniques, such as fluorescence and bioluminescence, offer a non-invasive, radiation-free approach to tumour visualisation. These methods rely on detecting light emitted by tumour-specific markers or fluorescent dyes. Optical imaging is particularly useful for studying tumour growth and response to treatment in preclinical models. However, the limited penetration of light in tissues can restrict its application in deep-seated tumours.
Tumour imaging has made significant strides in recent years, offering a variety of techniques to detect and monitor tumours effectively. Each imaging modality has its advantages and disadvantages, and the choice of method depends on factors such as tumour location, stage, and the patient’s overall health. As technology advances, tumour imaging will play an increasingly crucial role in the early detection and management of cancer, ultimately improving patient outcomes.
You are here:
home »
By | 10 minutes of readingYttrium-90 DOTA-FF-21101 targets P-Cadherin in solid tumours, delivering beta radiation for precise cancer treatment.
By | 12 minutes of readingRhenium-188 ImDendrim combines targeted nitro-imidazole ligands and dendrimers to deliver beta radiation to hypoxic tumours.
By | 5 minutes of readingProton therapy in cancer treatment offers precise targeting, reducing damage to healthy tissues and improving outcomes.
Exploring the Role of Proton Therapy in Cancer Treatment Read Post »
By | 4 minutes of readingPhosphorus-32 Colloidal Chromic Phosphate delivers precise beta radiation for treating malignant effusions and cystic tumours.
By | 5 minutes of readingBlastoma tumours require advanced imaging techniques like MRI, CT, PET, and ultrasound for accurate diagnosis and staging.
Imaging Techniques Used to Diagnose and Stage Blastoma Tumours Read Post »
By | 4 minutes of readingIntraoperative Avidination Radionuclide Treatment utilises avidin-biotin technology to deliver targeted tumour radiation therapy.
IART: A Precision Approach in Intraoperative Radionuclide Treatment Read Post »
By | 4 minutes of readingLutetium-177 Satoreotide Tetratexan is a radiopharmaceutical targeting somatostatin receptors, providing advanced therapeutic options for neuroendocrine neoplasms effectively.
By | 4 minutes of readingLutetium-177 Pentixather targets CXCR4-expressing tumours, delivering precise beta radiation therapy to eliminate malignant cells effectively.
By | 4 minutes of readingTargeting glioblastoma with Lutetium-177 ITM-31 offers precise intracavitary treatment, reducing recurrence by specifically addressing residual cancer cells post-surgery.
Targeting Glioblastoma with Precision: The Promise of Lutetium-177 ITM-31 Read Post »
By | 9 minutes of readingLutetium-177 DPI-4452 pioneers precision radiotheranostics, revolutionising treatment for CAIX-expressing solid tumours through targeted imaging, therapy, and personalised oncology care advancements.
By | 4 minutes of readingIodine-131 TM601, a synthetic radiolabelled peptide, targets tumour cells expressing Annexin A2, delivering therapeutic radiation and exhibiting anti-angiogenic properties effectively.
Iodine-131 TM601: Targeting Tumours with Radiolabelled Peptides Read Post »
By | 4 minutes of readingTLX101 is a revolutionary radiopharmaceutical targeting gliomas, offering dual imaging and therapy through tumour-selective uptake, enhancing treatment outcomes.
TLX101: A Pioneering Radiopharmaceutical for Glioma Diagnosis and Therapy Read Post »
By | 3 minutes of readingLinear Energy Transfer is vital for understanding radiation’s biological effects and optimising cancer radiation therapy.
By | 4 minutes of reading225Ac-FPI-1434 advances in clinical trials, targeting IGF-1R in chemo-resistant solid tumors with promising results.
By | 5 minutes of reading225Ac-DOTATOC advances GEP-NET treatment, offering targeted, effective therapy for patients resistant to traditional methods.
By | 15 minutes of readingCAR T-cell therapy revolutionises cancer care, bringing hope where traditional treatments have been insufficient.
By | 4 minutes of readingUltrasound Localization Microscopy offers unprecedented microvascular insights, transforming diagnosis and treatment through super-resolution imaging.
By | 3 minutes of readingPancreatic cancer demands accurate prognosis, improved treatment strategies, and PET radiomic analysis for optimised post-resection outcomes.
Prognostic Accuracy in Resected Pancreatic Cancer: Using Radiomic PET Imaging Read Post »
By | 3 minutes of readingLutetium-177 Dotatate selectively binds to SSTRs on NET cells, delivering targeted radiation, minimizing collateral damage, and reducing side effects.
Lutetium-177 Dotatate: A Novel Therapeutic Approach in Neuroendocrine Tumours Read Post »
By | 3 minutes of readingIodine-131 Iobenguane (I-131 MIBG), a radiopharmaceutical agent, enables early diagnosis and targeted treatment of neuroendocrine tumours, improving patient outcomes.
By | 13 minutes of readingTopics on PET imaging, automated radiosynthesis, breast cancer, prostate cancer therapy and ultrasound.
Inaugural editorial review: nuclear medicine, diagnostic imaging and therapy Read Post »
